Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers

Area of Science:

• Oncology
• Cancer Therapeutics
• Molecular Biology

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer with a high relapse rate, necessitating novel therapeutic strategies.
• Standard treatments face challenges due to cancer cell resistance, often mediated by DNA damage repair pathways.
• Targeting these pathways presents a promising avenue for improving treatment efficacy in HNSCC.

Purpose of the Study:

• To explore the potential of DNA repair targeted agents in combination with standard therapies for HNSCC.
• To identify key molecular targets within DNA damage repair pathways for therapeutic intervention.
• To review the current landscape of preclinical and clinical research on these agents in HNSCC.

Main Methods:

• Review of preclinical studies investigating DNA repair inhibitors (e.g., PARP, DNA-PK, PI3K, ATM, ATR, CHK1/2, WEE1 inhibitors) in HNSCC models.
• Analysis of ongoing and completed clinical trials evaluating these targeted agents in HNSCC patients.
• Discussion of the role of DNA damage repair pathways in HNSCC therapeutic resistance.

Main Results:

• Preclinical studies demonstrate promising efficacy of DNA repair targeted agents in HNSCC, often in combination regimens.
• Multiple clinical trials are underway, exploring various combinations and targets, indicating significant research interest.
• Challenges remain, including the need for robust biomarkers to predict patient response and guide treatment selection.

Conclusions:

• DNA repair targeted agents represent a significant advancement in HNSCC treatment research, offering new hope for patients.
• Further clinical investigation and biomarker development are crucial for translating preclinical success into FDA-approved therapies.
• Personalized treatment strategies incorporating DNA repair inhibitors may improve outcomes for HNSCC patients.